Trials / Unknown
UnknownNCT05833282
Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Tourcoing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.
Detailed description
INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU. PRIMARY ENDPOINT \- The primary endpoint is 30-day mortality.
Conditions
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2023-04-27
- Last updated
- 2023-04-27
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05833282. Inclusion in this directory is not an endorsement.